Tag Archive for ‘pancreatic cancer’
Clinical Trial Examines Postoperative Chemotherapy versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
The S2104 trial compares chemotherapy to observation following resection of pancreatic neuroendocrine tumors.
Role of radiation in the treatment of pancreatic adenocarcinoma in the neoadjuvant setting
Summarizes the findings of recent studies examining the role of radiation therapy in the treatment of pancreatic ductal adenocarcinoma in the contemporary neoadjuvant setting.
ALLIANCE A021806 examines perioperative vs. adjuvant chemotherapy for resectable pancreatic cancer
Summarizes comparative study data to determine the utility of delivering perioperative and adjuvant chemotherapy to cancer patients.
New trial aims to settle debate on the intensity of pancreatic cyst surveillance
Pancreatic cystic neoplasms occur in up to 20 percent of the U.S. adult population, and the incidence increases with more advanced age.1 In recent years, the prevalence of cystic neoplasms of the pancreas appears to be increasing as more patients undergo cross-sectional imaging in both the ambulatory and emergency setting. A recent study of patients […]
Ga-68 imaging changes clinical management of GI and pancreatic neuroendocrine tumors
Ga-68 positron emission tomography has improved the clinical management of gastrointestinal and pancreatic neuroendocrine tumors, and multiple studies are ongoing to define its optimal role in clinical practice.
Neoadjuvant and perioperative chemotherapy for localized pancreatic cancer: Leveraging small and large databases in the absence of Level 1 evidence
In the rapidly evolving clinical paradigms for localized pancreatic cancer, a combination of Level 1 data and large and small database studies can inform disease management.
Databases: Where math meets medicine
Balancing statistical relevance with clinician experience leads to innovative approaches to patient care.
Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial
The study design and findings of the PRODIGE 24/CCTG PA6 Trial are outlined, which showed improved survival with modified FOLFIRINOX for resected pancreatic cancer patients.
Coming next month in JACS, and online now: Distal cholangiocarcinoma and pancreas cancer
This news brief highlights a JACS article that examines the results of a distal cholangiocarcinoma and pancreatic cancer multi-institution study.
Two studies pave the way for preoperative therapy in pancreatic cancer patients
Pancreatic cancer is the fourth-most common cause of cancer-related death in the U.S. and is predicted to soon be the third-leading cause. Surgical resection with pancreatectomy has historically been viewed as offering the only chance for cure. However, achieving negative margins at surgery can be difficult, with positive surgical margins found in as many as […]
Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results
The clinical importance of the Alliance A021101 cooperative group study as well as the design of the trial itself are the focus of this month’s column.
Borderline resectable pancreatic cancer: Pushing the technical limits of surgery
This column discusses how multimodality therapy, including surgical resection, now represents a potential route to long-term survival for a group of patients with so-called “borderline resectable” cancers.
